Dr. Anna Kazanchyan

Anna Kazanchyan, MD has been a member of the company’s board of directors since December 2014. She is a biotechnology executive with 20 years of experience at Wall Street firms, biopharmaceutical companies, and as an entrepreneur. Since September 2016, Dr. Kazanchyan has been the CEO and Chairwoman at Saghmos Therapeutics, a company which she founded that is focused on the prevention of contrast-induced acute kidney injury. She is also the founder and Managing Partner since 2004 of Primary i-Research, LLC, where she provides due diligence to leading healthcare investment funds and evaluates investment prospects of biopharmaceutical companies based on the scientific, clinical, regulatory, and commercial outlook for their products. In addition, Dr. Kazanchyan has been an Executive Advisor to CEOs of biopharmaceutical companies (start-ups to global companies) on clinical development, regulatory, and commercial strategy, as well as business development and valuation. Previously, she was Senior Vice President, Business Development and Product Development at Ovid Therapeutics, a company focused on rare neurological disorders. Dr. Kazanchyan was also a Senior Biotechnology Analyst at Wachovia Securities, and was a member of the #1 and #2 Institutional-Investor ranked Biotechnology Equity Research teams at Goldman Sachs and Citigroup. She currently serves on the board of directors of Innovate Biopharmaceuticals (Nasdaq: INNT). Dr. Kazanchyan received an MD from Harvard Medical School and a BA in biology, summa cum laude, from Clark University.